



HIFU CANCER TREATMENT AND ULTRASONIC MEDICAL TECHNOLOGIES

Sonablate® 500 Takes Center Stage With Visually Directed HIFU

The Sonablate® 500 (SB500) (pictured below) focuses on the therapeutic treatment of cancer and benign tumors of the prostate. The medical device developed by Focus Surgery and manufactured and distributed in Europe by Misonix, uses High Intensity Focused Ultrasound (HIFU) to destroy deep-seated tissue without affecting surrounding healthy tissue.

Among the benefits of HIFU as compared to traditional modalities is its noninvasiveness and ability to spare surrounding tissue. Furthermore, there has been a groundswell of interest among surgeons and patients who are learning that the SB500 is the only device that doesn't require a Trans Urethral Resection of the Prostate (TURP) while at the same time treats significantly larger prostates than other HIFU treatments. TURPs mean that treatments require 2 procedures and are no longer considered minimally invasive.

Visually Directed HIFU is a new, non-invasive HIFU technique available only with the SB500. This process is credited for setting a much higher standard of care for prostate cancer treatment. As previously announced by Misonix, Visually Directed HIFU treatment results were reported by researchers from the Clinical Effectiveness Unit, the Royal College of Surgeons of England, London, UK, including Dr. Rowland Illing, Dr. Sam Dawkins, Dr. Chris Ogden and Dr. Mark Emberton. The study showed that with the new HIFU technique, a greater level of success was achieved as measured by reduced PSA nadir levels that are better than achieved by all other published non-invasive procedures and which are on par with results typically associated with a surgical approach. Recent results show that 84% of patients were able to achieve success as measured by PSA nadirs dropping to 0.2 ng/ml or less without a TURP procedure.



European HIFU Reimbursement

Country	Private Health Insurance	Public Health Insurance
BELGIUM	YES	NO
FRANCE	YES	YES
GERMANY	YES	YES
ITALY	YES	PARTIAL
NETHERLANDS	YES	NO
SPAIN	YES	NO
UK	YES	PARTIAL

SonicOne® Ultrasonic Wound Debridement System

A Necessary Treatment as Type 2 Diabetes Reaches Epidemic Proportions

According to the American Diabetes Association (ADA) (www.diabetes.org), there are 20.8 million children and adults in the US, or 7% of the population, who have diabetes, a condition related to insulin abnormalities. It is estimated that 90-95% of all cases of diabetes cases are Type 2. According to a New York Times article in May 2006, Type 2 diabetes most often affects the old and overweight and is the nation's fastest growing health problem.


While there are reported cases affecting all demographic groups, Type 2 diabetes is more common in African Americans, Latinos, Native Americans, and Asian Americans/Pacific Islanders, as well as the aged population. With a large baby boomer generation and people living longer, chronic illnesses such as Type 2 diabetes pose long term health conditions.

Among other serious side effects, the ADA estimates that one-third of people with diabetes will have a skin disorder caused or affected by diabetes. The body's limitations that result from diabetes can interfere with the skin's natural healing process. If a wound is left untreated or does not heal properly, it can become infected and develop into an ulcer. Ulcers put patients at risk for amputation. The National Institute of Health indicated that more than half of lower limb amputations in the US occur among people with diabetes. From 1993-1995, about 67,000 amputations were performed each year among people with diabetes. Specialists believe that nearly two-thirds of patients will experience recurrence of their wound ailments even after successful ulcer healing. This chronic condition is driving the demand for wound care treatment that is patient friendly and necessary to lower health care costs – two underlying benefits of Misonix's SonicOne® Ultrasonic Wound Debridement System.

The SonicOne removes necrotic tissue, biofilm, and other impediments for successful wound healing. Commercialization efforts for the SonicOne are underway with the recent distribution agreement signed with Medline Industries. Medline, a privately-held manufacturer and distributor of healthcare products with \$2 billion in annual sales, has been named the exclusive distributor for the device in the United States.



The SonicOne from Misonix



“I have noticed excellent granulation results with far less bleeding and scabbing than conventional surgical debridement. Most patients felt less pain, the amount of pain medication required was drastically reduced, and the patients felt great relief...” -- Dr. Carlo Caravaggi on using the SonicOne

CONTACT INFO:

Misonix, Inc.
1938 New Highway
Farmingdale, NY 11735
www.misonix.com
Nasdaq: MSON

Michael McManus, Jr.
President, CEO
631-694-9555

Jordan Darrow
Darrow Associates, Inc.
631-367-1866
Jdarrow@darrowir.com

Direct Costs of Diabetes

- Estimated at \$92 billion in 2002, compared to \$44 billion in 1997.
- Diabetes alone represents 11% of the US health care expenditure. People with diabetes have medical expenditures 2.4 times higher than they would if they did not have diabetes.
- \$40.3 billion was spent for inpatient hospital care and \$13.8 billion for nursing home care for people with diabetes.
- Diabetes-related hospitalizations totaled 16.9 million days in 2002. Rates of outpatient care were highest for physician office visits, which included 62.6 million visits to treat persons with diabetes.

Indirect Costs of Diabetes

- Estimated to be \$40 billion in 2002.
- In 2002, diabetes accounted for a loss of nearly 88 million disability days.
- 176,000 cases of permanent disability were caused by diabetes, at a cost of \$7.5 billion.

Source: ADA

Facts & Figures